Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyAnthony R. Mato, Michael Wang, Alvaro J. Alencar et al.|The Lancet|2021Cited by 456
Outcomes of COVID-19 in patients with CLL: a multicenter international experienceAnthony R. Mato, José‐Ángel Hernández‐Rivas, Lindsey E. Roeker et al.|Blood|2020Cited by 318
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.William G. Wierda, Hema Sundar, John C. Byrd et al.|PubMed|2020Cited by 143
COVID-19 in patients with CLL: improved survival outcomes and update on management strategiesLindsey E. Roeker, Sigrid S. Skånland, Toby A. Eyre et al.|Blood|2021Cited by 70
Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN StudyAnthony R. Mato, Wojciech Jurczak, John M. Pagel et al.|Blood|2021Cited by 15